We are pleased to share that from 1 August, Cariban® will no longer be subject to an approval process with reimbursement now available under the community drug schemes.
PCRS will facilitate claims of the EMP for approved patients under the old arrangement for one month (August 2024) to enable any existing EMP stock to be exhausted.
Any newly initiated/current patients presenting with a prescription for Cariban® and do not have approval for the EMP version, can be issued with the licenced version.
Please note that retrospective claims (January 2023 – July 2024) for those who did not have patient specific approval in place for Cariban® EMP will not be paid.
PCRS will release their circular today with full details.
Drug | Version | GMS Code | Patient |
Cariban® 10mg/10mg EMP | EMP | 66892 | Patients with approval in place |
Cariban® 10mg/10mg Galan | Licenced | 67209 | Newly initiated/current patients without approval in place |